Trial PaperAnxiety DisordersDepressive DisordersTreatment-Resistant Depression (TRD)Headache Disorders (Cluster & Migraine)SuicidalitySafety & Risk ManagementChronic PainPsilocybin

Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression

This double-blind active-placebo controlled trial (n=233) tested the effect of a single dose of psilocybin (25/10/1mg) with supportive therapy for treatment-resistant depression. The primary endpoint at three weeks finds a significant reduction in depressive symptoms (MADRS, 12-point drop from baseline of 32) that was significantly greater in the 25mg group vs the 1mg (placebo) group (6.6 points larger drop). The response (>50% drop in MADRS score) in the 25mg group dropped from 37% at 3 weeks to 20% at 12 weeks.

Authors

  • Robin Carhart-Harris
  • James Rucker
  • Allan Young

Published

New England Journal of Medicine
individual Study

Abstract

Background

Psilocybin is being studied for use in treatment-resistant depression.

Methods

In this phase 2 double-blind trial, we randomly assigned adults with treatment-resistant depression to receive a single dose of a proprietary, synthetic formulation of psilocybin [COMP360] at a dose of 25 mg, 10 mg, or 1 mg (control), along with psychological support. The primary endpoint was the change from baseline to week 3 in the total score on the Montgomery-Åsberg Depression Rating Scale (MADRS; range, 0 to 60, with higher scores indicating more severe depression). Secondary endpoints included response at week 3 (≥50% decrease from baseline in the MADRS total score), remission at week 3 (MADRS total score ≤10), and sustained response at 12 weeks (meeting response criteria at week 3 and all subsequent visits).

Results

A total of 79 participants were in the 25-mg group, 75 in the 10-mg group, and 79 in the 1-mg group. The mean MADRS total score at baseline was 32 or 33 in each group. Least-squares mean changes from baseline to week 3 in the score were −12.0 for 25 mg, −7.9 for 10 mg, and −5.4 for 1 mg; the difference between the 25-mg group and 1-mg group was −6.6 (95% confidence interval [CI], −10.2 to −2.9; P<0.001) and between the 10-mg group and 1-mg group was −2.5 (95% CI, −6.2 to 1.2; P=0.18). In the 25-mg group, the incidences of response and remission at 3 weeks, but not sustained response at 12 weeks, were generally supportive of the primary results. Adverse events occurred in 179 of 233 participants (77%) and included headache, nausea, and dizziness. Suicidal ideation or behavior or self-injury occurred in all dose groups.

Conclusion

In this phase 2 trial involving participants with treatment-resistant depression, psilocybin at a single dose of 25 mg, but not 10 mg, reduced depression scores significantly more than a 1-mg dose over a period of 3 weeks but was associated with adverse effects. Larger and longer trials, including comparison with existing treatments, are required to determine the efficacy and safety of psilocybin for this disorder.

Available with Blossom Pro

Research Summary of 'Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression'

Introduction

Treatment-resistant depression is described as a difficult-to-treat condition with progressively lower remission rates after successive antidepressant trials, as shown in the STAR*D series (first through fourth courses: 36.8%, 30.6%, 13.7%, and 13.0%, respectively). Failure of two adequate antidepressant trials is commonly used to define treatment-resistant depression, and affected patients have greater illness severity, chronicity, disability, health comorbidity, hospitalisation, suicide risk, and economic burden than those with treatment-responsive depression. Psilocybin, a tryptamine alkaloid found in psilocybe mushrooms, has shown antidepressant potential in preliminary studies in cancer-related depression and in small pilot studies of major depressive disorder, including some work in treatment-resistant populations and trials comparing psilocybin with escitalopram. Goodwin and colleagues designed the present study to identify an acceptable efficacious dose and to assess the safety of a proprietary, synthetic formulation of psilocybin (COMP360) given as a single dose together with psychological support in adults with a treatment-resistant major depressive episode. The trial aimed to test two active dose levels (25 mg and 10 mg) against a very low-dose control (1 mg) with a primary efficacy assessment at 3 weeks and follow-up to 12 weeks.

Expert Research Summaries

Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.

See Pro PlansAlready have an account? Sign in

Study Details

References (6)

Papers cited by this study that are also in Blossom

The pharmacology of psilocybin

Passie, T., Seifert, J., Schneider, U. et al. · Addiction Biology (2002)

Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: A randomized controlled trial

Ross, S., Bossis, A. P., Guss, J. et al. · Journal of Psychopharmacology (2016)

Trial of Psilocybin versus Escitalopram for Depression

Carhart-Harris, R. L., Giribaldi, B., Watts, R. et al. · New England Journal of Medicine (2021)

927 cited
Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study

Carhart-Harris, R. L., Bolstridge, M., Rucker, J. et al. · Lancet Psychiatry (2016)

1174 cited
Development and Evaluation of a Therapist Training Program for Psilocybin Therapy for Treatment-Resistant Depression in Clinical Research

Nielson, E. M., Tai, S. J., Lennard-Jones, M. et al. · Frontiers in Psychiatry (2021)

75 cited
Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels

Madsen, M. K., Fisher, P. M., Burmester, D. et al. · Neuropsychopharmacology (2019)

Cited By (142)

Papers in Blossom that reference this study

Synergies in psychedelic-assisted therapy: a qualitative interview study of psychotherapeutic processes

Stellmacher, J., Schmidt, C., Aicher, H. D. et al. · Frontiers in Psychiatry (2026)

Psychedelics in NHS services: exploring a model for real-world implementation of psilocybin

Smith, K. A., Harcourt, E., Cipriani, A. · BJPsych Open (2026)

Dose-dependent pharmacokinetics and acute effects of intravenous bolus N,N-dimethyltryptamine: double-blind, randomized versus open-label dose-escalation administration study in healthy participants

Erne, L., Mueller, L., Straumann, I. et al. · Translational Psychiatry (2026)

GH001 vs Placebo in Patients With Treatment-Resistant Depression A Randomized Clinical Trial

Cubała, W. J., Bajbouj, M., Bauer, M. et al. · JAMA Psychiatry (2026)

The role of therapeutic alliance in psilocybin treatment for treatment-resistant depression: A post hoc path analysis

Goodwin, G. M., Aaronson, S. T., Alvarez, O. et al. · Journal of Affective Disorders (2026)

Trip killers: Addressing a critical knowledge gap in psychedelic research

O’Mahony, B., Harrington, C., Harkin, A. et al. · Journal of Psychopharmacology (2026)

Psychedelic Therapy vs Antidepressants for the Treatment of Depression Under Equal Unblinding Conditions A Systematic Review and Meta-Analysis

Williams, Z. J., Barnett, H., Szigeti, B. · JAMA Psychiatry (2026)

Efficacy and Safety of Psilocybin in Treatment-Resistant Major Depression: The EPISODE Randomized Clinical Trial

Mertens, L. J., Koslowski, M., Betzler, F. et al. · JAMA Psychiatry (2026)

A phase 2 uncontrolled, open-label study of intranasal BPL-003 (5-methoxy-N,N-dimethyltryptamine) in patients with treatment-resistant depression

Roberts, C., Seynaeve, M., Ermakova, A. O. et al. · Journal of Psychopharmacology (2026)

Pilot study of psilocybin in patients with post-treatment lyme disease

Garcia-Romeu, A., Naudé, G. P., Rebman, A. W. et al. · Scientific Reports (2026)

Show all 142 papers
Psychedelic medicine: mechanisms, evidence, and translation to practice

Jacobs, E., Zahid, Z., Hinkle, J. et al. · BMJ (2026)

Magnitude of Response in Treatment and Control Groups within Psychedelic Trials for Psychiatric Disorders: A Meta-Analysis

Meshkat, S., Lin, Q., Sousa-Ho, R. et al. · European Psychiatry (2026)

Trip sitting or just sitting? Session facilitators substantially influence psychedelic experiences in clinical trials but not in healthy ones

Goldy, S. P., Sepeda, N. D., Hilbert, S. N. et al. · Psychiatry Research (2026)

1 cited
An open-label pilot study of psilocybin-assisted therapy for binge eating disorder

Dallery, J., Miller, J. L., Boissoneault, J. et al. · Journal of Eating Disorders (2026)

Psychedelics: The pathway to implementation in the European healthcare systems

Gründer, G., Mertens, L. J., Spangemacher, M. et al. · European Neuropsychopharmacology (2026)

Effects of LSD and Psilocybin on Heart Rate in Patients Receiving Psychedelic Treatment for Depressive and Anxiety Disorders: A Retrospective Observational Study

Cheng, M., Aboulafia-Brakha, T., Buchard, A. et al. · Psychology International (2025)

Real-World Psilocybin Therapy for Treatment-Resistant Depression: a Retrospective Observational Study

Jungwirth, J., Westenhöfer, S., Aicher, H. et al. · Preprints (2025)

Acute and post-dosing effects of single-dose psilocybin for obsessive-compulsive disorder in a randomized, double-blind, placebo-controlled trial: an interpretative phenomenological analysis

Ching, T. H. W., Stahnke, B., Shnayder, S. et al. · Frontiers in Psychiatry (2025)

The Relationship Between Participant Pretreatment Clinical Presentation and the Quality of Psilocybin Experience: A Retrospective Analysis

Kirlić, N., Atli, M., Mistry, S. et al. · Journal of Clinical Psychopharmacology (2025)

Investigational psilocybin treatment for post-traumatic stress disorder: a qualitative study of participant experience, trauma engagement, and differences from standard treatment

Modlin, N. L., Williamson, V., Goodwin, G. M. et al. · EClinicalMedicine (2025)

1 cited
Cognitive outcomes following psilocybin-assisted therapy in treatment-resistant depression: A post-hoc analysis of a randomized, waitlist-controlled trial

Johnson, D. E., Meshkat, S., Kaczmarek, E. S. et al. · Progress in Neuro-Psychopharmacology and Biological Psychiatry (2025)

Naturalistic psychedelic use and changes in depressive symptoms

Simonsson, O., Hendricks, P. S., Swords, C. M. et al. · Journal of Affective Disorders (2025)

Negative affective bias in depression following treatment with psilocybin or escitalopram - a secondary analysis from a randomized trial

Martens, M. A. G., Cunha, B. G., Erritzoe, D. et al. · Translational Psychiatry (2025)

Long-term outcomes of single-dose psilocybin for U.S. military Veterans with severe treatment-resistant depression - 12-month data from an open-label pilot study

Ellis, S., Bostian, C., Donnelly, A. et al. · Journal of Affective Disorders (2025)

Single Treatment With MM120 (Lysergide) in Generalized Anxiety Disorder: A Randomized Clinical Trial

Robison, R., Barrow, R., Conant, C. et al. · JAMA (2025)

7 cited
A novel psychedelic 5-HT2A receptor agonist GM-2505: The pharmacokinetic, safety, and pharmacodynamic profile from a randomized trial healthy volunteer

Marek, G. J., Makai-Bölöni, S., Umbricht, D. et al. · Journal of Psychopharmacology (2025)

Psilocybin’s effect on human brain synaptic plasticity

Johansen, A., Plavén-Sigray, P., Madsen, M. K. et al. · Research Square (2025)

Psilocybin with psychotherapeutic support for treatment-resistant depression: a pilot clinical trial

Meikle, S., Carter, O., Liknaitzky, P. et al. · Therapeutic Advances in Psychopharmacology (2025)

Single-dose (10 mg) psilocybin reduces symptoms in adults with obsessive-compulsive disorder: A pharmacological challenge study

Pellegrini, L., Fineberg, N. A., O'Connor, S. et al. · Comprehensive Psychiatry (2025)

Efficacy and safety of low- versus high-dose-LSD-assisted therapy in patients with major depression: A randomized trial

Mu, F., Zaczek, H., Becker, A. M. et al. · Med (2025)

7 cited
Investigating the safety and tolerability of single-dose psilocybin for post-traumatic stress disorder: A nonrandomized open-label clinical trial

Mcgowan, N. M., Rucker, J. J., Yehuda, R. et al. · Journal of Psychopharmacology (2025)

5 cited
Control Group Outcomes in Trials of Psilocybin, SSRIs, or Esketamine for Depression: A Meta-Analysis

Hieronymus, F., López, E., Sjögren, H. W. et al. · JAMA Network Open (2025)

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneous RE104: A Double-Blind, Randomized, Single Ascending Dose Placebo-Controlled Study

Ludbrook, G., Bryson, N., Taylor, B. et al. · Journal of Clinical Psychopharmacology (2025)

The polypharmacology of psychedelics reveals multiple targets for potential therapeutics

Jain, M. K., Gumpper, R. H., Slocum, S. T. et al. · Neuron (2025)

Pharmacokinetics, Pharmacodynamics, and Urinary Recovery of Oral Mescaline Hydrochloride in Healthy Participants

Mueller, L., Klaiber, A., Ley, L. et al. · Clinical Pharmacokinetics (2025)

Psilocybin treatment extends cellular lifespan and improves survival of aged mice

Kato, K., Kleinhenz, J. M., Shin, Y. J. et al. · npj Aging (2025)

An open-label, dose-escalation trial of psilocybin-assisted therapy for bipolar 2 depression

Downey, A. E., Szigeti, B., Bradley, E. R. et al. · OSF Preprints (2025)

The phenomenology of psilocybin's experience mediates subsequent persistent psychological effects independently of sex, previous experience, or setting

Tylš, F., Páleníček, T., Klučková, T. et al. · Pharmacological Reports (2025)

3 cited
‘Equal-unblinding’ meta-analysis of psychedelic therapy vs. antidepressants for the treatment of depression

Williams, Z. J., Barnett, H., Szigeti, B. · OSF Preprints (2025)

Enhanced meaning in life following psychedelic use: converging evidence from controlled and naturalistic studies

Roseby, W., Kettner, H., Roseman, L. et al. · Frontiers in Psychology (2025)

Psilocybin’s acute and persistent brain effects: a precision imaging drug trial

Subramanian, S., Renau, R., Perry, D. et al. · Scientific Data (2025)

2 cited
Assessing the Potential Cardiovascular Risk of Microdosing the Psychedelic LSD in Mice

Effinger, D. P., Schalk, S. S., King, J. L. et al. · ACS Pharmacology and Translational Science (2025)

A multi-institutional investigation of psilocybin's effects on mouse behavior

Lu, O. D., White, K., Raymond, K. et al. · Biorxiv (2025)

Psilocybin therapy for mood dysfunction in Parkinson's disease: an open-label pilot trial

Bradley, E. R., Sakai, K., Fernandes-Osterhold, G. et al. · Neuropsychopharmacology (2025)

10 cited
Psilocybin’s lasting action requires pyramidal cell types and 5-HT2A receptors

Shao, L-X,, Tan, D., Liao, C., Davoudian, P. A. et al. · Nature Communications (2025)

Psilocybin-assisted therapy for relapse prevention in alcohol use disorder: a phase 2 randomized clinical trial

Rieser, N. M., Bitar, R., Halm, S. et al. · EClinicalMedicine (2025)

Comparing Antidepressant Effects of Psilocybin-Assisted Psychotherapy in Individuals That Were Unmedicated at Initial Screening Versus Individuals Discontinuing Medications for Study Participation

Chisamore, N., Kaczmarek, E. S., Doyle, Z. et al. · Canadian Journal of Psychiatry (2025)

Preliminary safety and effectiveness of psilocybin-assisted therapy in adults with fibromyalgia: An open-label, proof-of-concept clinical trial

Aday, J. S., Mcafee, J., Conroy, D. A. et al. · Frontiers in Pain Research (2025)

The role of the psychedelic experience in psilocybin treatment for treatment-resistant depression

Goodwin, G. M., Aaronson, S. T., Alvarez, O. et al. · Journal of Affective Disorders (2025)

28 cited
Acute Effects and Pharmacokinetics of LSD after Paroxetine or Placebo Pre-Administration in a Randomized, Double-Blind, Cross-Over Phase I Trial

Becker, A. M., Humbert-Droz, M., Mueller, L. et al. · Clinical Pharmacology and Therapeutics (2025)

Single-dose psilocybin therapy for alcohol use disorder: Pharmacokinetics, feasibility, safety and efficacy in an open-label study

Fink-Jensen, A., Jensen, M. E., Stenbæk, D. S. et al. · Journal of Psychopharmacology (2025)

Psilocybin-Assisted Psychotherapy for Treatment-Resistant Depression in Bipolar II Disorder

Meshkat, S., Kaczmarek, E., Doyle, Z. et al. · Psychedelic Medicine (2025)

Pharmacokinetics and Pharmacodynamics of an Innovative Psychedelic N,N-Dimethyltryptamine/Harmine Formulation in Healthy Participants: A Randomized Controlled Trial

Mueller, J., Mueller, M. J., Aicher, H. D. et al. · International Journal of Neuropsychopharmacology (2025)

A review of psychedelics trials completed in depression, informed by European regulatory perspectives

Silva, F., Butlen-Ducuing, F., Guizzaro, L. et al. · Neuroscience Applied (2025)

1 cited
Compass Psychological Support Model for COMP360 Psilocybin Treatment of Serious Mental Health Conditions

Kirlic, N., Lennard-Jones, M., Atli, M. et al. · American Journal of Psychiatry (2025)

Psilocybin-Assisted Group Psychotherapy + Mindfulness Based Stress Reduction (MBSR) for Frontline Healthcare Provider COVID-19 Related Depression and Burnout: A Randomized Clinical Trial

Lewis, B. R., Hendrick, J., Byrne, K. et al. · PLOS Medicine (2025)

Single-Dose Psilocybin for Depression With Severe Treatment Resistance: An Open-Label Trial

Aaronson, S. T., Van Der Vaart, A., Miller, T. et al. · American Journal of Psychiatry (2025)

Single-dose psilocybin for U.S. military Veterans with severe treatment-resistant depression - A first-in-kind open-label pilot study

Ellis, S., Bostian, C., Feng, W. et al. · Journal of Affective Disorders (2025)

The Australia story: Current status and future challenges for the clinical applications of psychedelics

Nutt, D. J., Hunt, P., Schlag, A. K. et al. · British Journal of Clinical Pharmacology (2024)

Psilocybin increases emotional empathy in patients with major depression

Jungwirth, J., Von Rotz, R., Dziobek, I. et al. · Molecular Psychiatry (2024)

9 cited
Quality of reporting on psychological interventions in psychedelic treatments: a systematic review

Seybert, C., Schimmers, N., Silva, L. et al. · Lancet (2024)

Psilocybin Therapy for Clinicians With Symptoms of Depression From Frontline Care During the COVID-19 Pandemic

Back, A., Freeman-Young, T. K., Morgan, L. et al. · JAMA Network Open (2024)

18 cited
Synergistic, multi-level understanding of psychedelics: three systematic reviews and meta-analyses of their pharmacology, neuroimaging and phenomenology

Shinozuka, K., Jerotic, K., Mediano, P. A. M. et al. · Translational Psychiatry (2024)

Adverse Events in Studies of Classic Psychedelics: A Systematic Review and Meta-Analysis

Hinkle, J. T., Graziosi, M., Nayak, S. et al. · JAMA Psychiatry (2024)

84 cited
The Impact of Antidepressant Discontinuation Prior to Treatment with Psilocybin for Treatment-Resistant Depression

Marwood, L., Croal, M., Mistry, S. et al. · Journal of Psychiatric Research (2024)

Reconsidering evidence for psychedelic-induced psychosis: an overview of reviews, a systematic review, and meta-analysis of human studies

Sabé, M., Sulstarova, A., Glangetas, A. et al. · Molecular Psychiatry (2024)

Major life changes following psychedelic use: A retrospective survey among people using psychedelics naturalistically

Aday, J. S., Glynos, N., Baker, A. et al. · Preprints (2024)

Structural neural plasticity evoked by rapid-acting antidepressant interventions

Liao, C., Dua, A. N., Wojtasiewicz, C. et al. · Nature Reviews Neuroscience (2024)

Enhanced visual contrast suppression during peak psilocybin effects: Psychophysical results from a pilot randomized controlled trial

Swanson, L. R., Jungers, S., Varghese, R. et al. · Journal of Vision (2024)

The non-hallucinogenic serotonin 1B receptor is necessary for the antidepressant-like effects of psilocybin in mice

Fleury, S., Nautiyal, K. M. · Biorxiv (2024)

Human brain changes after first psilocybin use

Lyons, T., Spriggs, M. J., Kerkelä, L. et al. · Biorxiv (2024)

Meta-correlation of the effect of ketamine and psilocybin induced subjective effects on therapeutic outcome

Dahan, J. D. C., Dadiomov, D., Bostoen, T. et al. · npj Mental Health Research (2024)

Effect of psilocybin versus escitalopram on depression symptom severity in patients with moderate-to-severe major depressive disorder: observational 6-month follow-up of a phase 2, double-blind, randomised, controlled trial

Erritzoe, D., Barba, T., Greenway, K. T. et al. · EClinicalMedicine (2024)

Low-dose psilocybin in short-lasting unilateral neuralgiform headache attacks: results from an open-label phase Ib ascending dose study

Rucker, J., Butler, M., Hambleton, S. et al. · Headache (2024)

Naturalistic psychedelic therapy: The role of relaxation and subjective drug effects in antidepressant response

Calder, A. E., Rausch, B., Liechti, M. E. et al. · Journal of Psychopharmacology (2024)

An estimate of the number of people with clinical depression eligible for psilocybin-assisted therapy in the United States

Rab, S. F., Raison, C. L., Marseille, E. · Psychedelics (2024)

Co-administration of midazolam and psilocybin: Differential effects on subjective quality versus memory of the psychedelic experience

Nicholas, C. R., Banks, M. I., Lennertz, R. L. et al. · Translational Psychiatry (2024)

Clinically relevant acute subjective effects of psychedelics beyond mystical experience

Yaden, D. B., Goldy, S. P., Weiss, B. et al. · Nature Reviews Psychology (2024)

Comparison between Single-Dose and Two-Dose Psilocybin Administration in the Treatment of Major Depression: A Systematic Review and Meta-Analysis of Current Clinical Trials

Salvetti, G., Saccenti, D., Moro, A. S. et al. · Brain Sciences (2024)

Psilocybin desynchronizes brain networks

Nicol, G. E. · Nature (2024)

160 cited
Attitudes of psychedelic users regarding cost of treatment and non-hallucinogenic alternatives

Aday, J. S., Boehnke, K. F., Herberholz, M. et al. · Journal of Psychedelic Studies (2024)

Psychedelic-assisted psychotherapy: Where is the psychotherapy research?

Aday, J. S., Horton, D. M., Fernandes-Osterhold, G. et al. · Psychopharmacology (2024)

Novel extended-release transdermal formulations of the psychedelic N,N-dimethyltryptamine (DMT)

Witowski, C. G., Hess, M. R., Jones, N. T. et al. · European Journal of Pharmacology (2024)

Structural pharmacology and therapeutic potential of 5-methoxytryptamines

Warren, A. L., Lankri, D., Cunningham, M. J. et al. · Nature (2024)

Effective-connectivity of thalamocortical interactions following d-amphetamine, LSD, and MDMA administration

Avram, M., Müller, F., Preller, K. H. et al. · Biological Psychiatry (2024)

13 cited
The Effect of Psychedelics on Individuals with a Personality Disorder: Results from two Prospective Cohort Studies

Gordon, A. R., Carrithers, B. M., Pagni, B. A. et al. · Research Square (2024)

Psychological flexibility as a mechanism of change in psilocybin-assisted therapy for major depression: results from an exploratory placebo-controlled trial

Sloshower, J. A., Zeifman, R. J., Guss, J. et al. · Scientific Reports (2024)

Mind the Psychedelic Hype: Characterizing the Risks and Benefits of Psychedelics for Depression

Meling, D., Ehrenkra, R., Nayak, S. et al. · Psychoactives (2024)

Phase 1, placebo-controlled, single ascending dose trial to evaluate the safety, pharmacokinetics and effect on altered states of consciousness of intranasal BPL-003 (5-methoxy-N,N-dimethyltryptamine benzoate) in healthy participants

Rucker, J., Roberts, C. A., Seynaeve, M. et al. · Journal of Psychopharmacology (2024)

20 cited
A comparison between psilocybin and esketamine in treatment-resistant depression using number needed to treat (NNT): A systematic review

Wong, S., Kwan, A. T. H., Teopiz, K. M. et al. · Journal of Affective Disorders (2024)

17 cited
Psilocybin enhances insightfulness in meditation: a perspective on the global topology of brain imaging during meditation

Berit, S., Meling, D., Hirsch-Hoffmann, M. et al. · Scientific Reports (2024)

The therapeutic alliance between study participants and intervention facilitators is associated with acute effects and clinical outcomes in a psilocybin-assisted therapy trial for major depressive disorder

Levin, A. W., Lancelotta, R., Sepeda, N. D. et al. · PLOS ONE (2024)

48 cited
Psychiatric risks for worsened mental health after psychedelic use

Marrocu, A., Kettner, H., Weiss, B. et al. · Journal of Psychopharmacology (2024)

41 cited
Psilocybin-assisted psychotherapy for treatment resistant depression: A randomized clinical trial evaluating repeated doses of psilocybin

Rosenblat, J. D., Meshkat, S., Doyle, Z. et al. · Med (2024)

Safety and tolerability of inhaled N,N-Dimethyltryptamine (BMND01 candidate): A phase I clinical trial

Falchi, M., Wießner, I., Silva, S. R. B. et al. · European Neuropsychopharmacology (2024)

18 cited
Effects of DMT on mental health outcomes in healthy volunteers

Timmermann, C., Zeifman, R. J., Erritzoe, D. et al. · Scientific Reports (2024)

29 cited
Psilocybin-induced changes in neural reactivity to alcohol and emotional cues in patients with alcohol use disorder: an fMRI pilot study

Pagni, B. A., Petridis, P. D., Podrebarac, S. K. et al. · Scientific Reports (2024)

20 cited
Psychedelics and sexual functioning: a mixed-methods study

Barba, T., Kettne, H., Radu, C. et al. · Scientific Reports (2024)

19 cited
Patient perspectives and experiences with psilocybin treatment for treatment-resistant depression: a qualitative study

Breeksema, J. J., Niemeijer, A. R., Krediet, E. et al. · Scientific Reports (2024)

Strong Bipartisan Support for Controlled Psilocybin Use as Treatment or Enhancement in a Representative Sample of US Americans: Need for Caution in Public Policy Persists

Sandbrink, J. D., Johnson, K., Gill, M. et al. · AJOB Neuroscience (2024)

10 cited
Who Are You After Psychedelics? A Systematic Review and a Meta-Analysis of the Magnitude of Long-Term Effects of Serotonergic Psychedelics on Cognition/Creativity, Emotional Processing and Personality

Solaja, I., Haldane, K., Mason, N. et al. · Neuroscience and Biobehavioral Reviews (2024)

Synthetic surprise as the foundation of the psychedelic experience

De Filippo, R., Schmitz, D. · Neuroscience and Biobehavioral Reviews (2024)

Older adults in psychedelic-assisted therapy trials: A systematic review

Bouchet, L., Sager, Z., Yrondi, A. et al. · Journal of Psychopharmacology (2024)

Greater subjective effects of a low dose of LSD in participants with depressed mood

Molla, H. M., Lee, R., Tare, I. et al. · Neuropsychopharmacology (2023)

30 cited
Overcoming the clinical challenges of traditional ayahuasca: a first-in-human trial exploring novel routes of administration of N,N-Dimethyltryptamine and harmine

Dornbierer, D. A., Marten, L., Mueller, J. et al. · Frontiers in Pharmacology (2023)

Epidemiology of classic psychedelic substances: results from a Norwegian internet convenience sample

Kvam, T-M., Uthaug, M. V., Andersen, K. A. A. et al. · Frontiers in Psychiatry (2023)

17 cited
Beyond the 5-HT2A Receptor: Classic and Nonclassic Targets in Psychedelic Drug Action

Cameron, L. P., Benetatos, J., Lewis, V. et al. · Journal of Neuroscience (2023)

45 cited
Extended difficulties following the use of psychedelic drugs: A mixed methods study

Evans, J., Robinson, O., Ketzitzidou-Argyri, E. et al. · PLOS ONE (2023)

123 cited
Psychedelic use and psychiatric risks

Simonsson, O., Goldberg, S. B., Chambers, R. et al. · Psychopharmacology (2023)

Cellular rules underlying psychedelic control of prefrontal pyramidal neurons

Ekins, T. G., Brooks, I., Kailasa, S. et al. · Biorxiv (2023)

Psilocybin-assisted therapy for depression: A systematic review and meta-analysis

Haikazian, S., Chen-Li, D., Johnson, D. et al. · Psychiatry Research (2023)

Psilocybin-induced changes in cerebral blood flow are associated with acute and baseline inter-individual differences

Rieser, N. M., Gubser, L. P., Moujaes, F. et al. · Scientific Reports (2023)

9 cited
Alternative beliefs in psychedelic drug users

Lebedev, A. V., Acar, K., Horntvedt, O. et al. · Scientific Reports (2023)

Mechanisms and molecular targets surrounding the potential therapeutic effects of psychedelics

Jaster, A. M., González-Maeso, J. · Molecular Psychiatry (2023)

History repeating: guidelines to address common problems in psychedelic science

Van Elk, M., Fried, E. I. · Therapeutic Advances in Psychopharmacology (2023)

94 cited
Naturalistic psilocybin use is associated with persisting improvements in mental health and wellbeing: results from a prospective, longitudinal survey

Nayak, S., Jackson, H., Sepeda, N. D. et al. · Frontiers in Psychiatry (2023)

Pharmacokinetics, pharmacodynamics and urinary recovery of oral lysergic acid diethylamide (LSD) administration in healthy participants

Friederike, H., Liechti, M. E., Holze, F. et al. · British Journal of Clinical Pharmacology (2023)

Single-Dose Psilocybin Treatment for Major Depressive Disorder: A Randomized Clinical Trial

Raison, C. L., Sanacora, G., Woolley, J. D. et al. · JAMA (2023)

375 cited
Persons With Spinal Cord Injury Report Peripherally Dominant Serotonin-Like Syndrome After Use of Serotonergic Psychedelics

Abrams, S. K., Rabinovitch, B. S., Zafar, R. et al. · Neurotherapeutics (2023)

Psilocybin-assisted therapy for depression: A systematic review and dose-response meta-analysis of human studies

Pereira, L. · European Neuropsychopharmacology (2023)

Psychedelic Use Among Psychiatric Medication Prescribers: Effects on Well-Being, Depression, Anxiety, and Associations with Patterns of Use, Reported Harms, and Transformative Mental States

Herrmann, Z., Levin, A. W., Cole, S. P. et al. · Psychedelic Medicine (2023)

Slouching towards engagement: interactions between people using psychedelics naturalistically and their healthcare providers

Boehnke, K. F., Cox, K., Weston, C. et al. · Frontiers in Psychiatry (2023)

How does psilocybin therapy work? An exploration of experiential avoidance as a putative mechanism of change

Zeifman, R. J., Wagner, A. C., Monson, C. M. et al. · Journal of Affective Disorders (2023)

47 cited
The Relationship Between Naturalistic Psychedelic Use and Clinical Care in Canada

Glynos, N., Kruger, D. J., Kolbman, N. et al. · Journal of Psychoactive Drugs (2023)

9 cited
Therapeutic mechanisms of psychedelics and entactogens

Heifets, B. D., Olson, D. E. · Neuropsychopharmacology (2023)

Dark loops: contagion effects, consistency and chemosocial matrices in psychedelic-assisted therapy trials

Noorani, T. N., Bedi, G., Muthukumaraswamy, S. · Psychological Medicine (2023)

21 cited
Must Psilocybin Always “Assist Psychotherapy”?

Goodwin, G. M., Malievskaia, E., Fonzo, G. A. et al. · American Journal of Psychiatry (2023)

Navigating the chaos of psychedelic neuroimaging: A multi-metric evaluation of acute psilocybin effects on brain entropy

McCulloch, D. E-W., Olsen, A. S., Ozenne, B. et al. · MedRvix (2023)

12 cited
Overcoming blinding confounds in psychedelic randomized controlled trials using biomarker driven causal mediation analysis

Muthukumaraswamy, S. · Psyarxiv (2023)

Assessment of the acute effects of 2C-B vs psilocybin on subjective experience, mood and cognition

Mallaroni, P., Mason, N. L., Reckweg, J. T. et al. · Clinical Pharmacology and Therapeutics (2023)

39 cited
Attenuation of psilocybin mushroom effects during and after SSRI/SNRI antidepressant use

Griffiths, R. R., Yaden, D. B., Nayak, S. et al. · Journal of Psychopharmacology (2023)

44 cited
Personality change in a trial of psilocybin therapy v. escitalopram treatment for depression

Weiss, B., Ginige, I., Shannon, L. et al. · Psychological Medicine (2023)

Reducing the Harms of Nonclinical Psychedelics Use Through a Peer-Support Telephone Helpline

Pleet, M. M., White, J., Zamaria, J. A. et al. · Psychedelic Medicine (2023)

Changed Substance Use After Psychedelic Experiences Among Individuals in Canada

Boehnke, K. F., Kruger, D. J., Lucas, P. · International Journal of Mental Health and Addiction (2023)

11 cited
Human brain effects of DMT assessed via EEG-fMRI

Timmermann, C., Roseman, L., Haridas, S. et al. · PNAS (2023)

158 cited
Canalization and plasticity in psychopathology

Carhart-Harris, R. L., Chandaria, S., Erritzoe, D. E. et al. · Neuropharmacology (2023)

The therapeutic potential of psychedelics: the European regulatory perspective

Butlen-Ducuing, F., McCulloch, D. E-W., Haberkamp, M. et al. · Lancet (2023)

A neurophenomenological approach to non-ordinary states of consciousness: hypnosis, meditation, and psychedelics

Timmermann, C., Vollenweider, F. X. · Trends in Cognitive Sciences (2023)

Single-dose psilocybin-assisted therapy in major depressive disorder: A placebo-controlled, double-blind, randomised clinical trial

Schindowski, E. M., Jungwirth, J., Schuldt, A. et al. · EClinicalMedicine (2023)

5-HT2ARs Mediate Therapeutic Behavioral Effects of Psychedelic Tryptamines

Cameron, L. P., Patel, S. D., Vargas, M. V. et al. · ACS Chemical Neuroscience (2023)

86 cited
The effect of lysergic acid diethylamide (LSD) on whole-brain functional and effective connectivity

Bedford, P., Hauke, D. J., Wang, Z. et al. · Neuropsychopharmacology (2022)

Psychedelic therapy for depressive symptoms: A systematic review and meta-analysis

Kopra, E., Cleare, A. J., Rucker, J. et al. · Journal of Affective Disorders (2022)

Your Personal Research Library

Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.

See Pro PlansSign in